Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334


Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, Buzza M, Gledhill S, Zhang L, Galvão DA, Ryan CJ, Saad F.

BMJ Open. 2018 May 14;8(5):e022899. doi: 10.1136/bmjopen-2018-022899.


At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials.

Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ.

Oncologist. 2018 Apr 26. pii: theoncologist.2017-0628. doi: 10.1634/theoncologist.2017-0628. [Epub ahead of print]


Impact of Medicare Advantage penetration and hospital competition on technical efficiency of nursing care in US intensive care units.

Min A, Scott LD, Park C, Vincent C, Ryan CJ, Lee T.

Int J Health Plann Manage. 2018 Apr 10. doi: 10.1002/hpm.2528. [Epub ahead of print]


The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, John Francis PS, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Apr 6. pii: S0022-5347(18)42900-X. doi: 10.1016/j.juro.2018.03.125. [Epub ahead of print]


E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.


A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.

Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ.

Oncologist. 2018 Feb 27. pii: theoncologist.2017-0624. doi: 10.1634/theoncologist.2017-0624. [Epub ahead of print]


Community treatment orders: towards a new research agenda.

Brophy L, Edan V, Gooding P, McSherry B, Burkett T, Carey S, Carroll A, Callaghan S, Finch A, Hansford M, Hanson S, Kisely S, Lawn S, Light E, Maher S, Patel G, Ryan CJ, Saltmarsh K, Stratford A, Tellez JJ, Toko M, Weller P.

Australas Psychiatry. 2018 Feb 1:1039856218758543. doi: 10.1177/1039856218758543. [Epub ahead of print]


Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L.

Clin Genitourin Cancer. 2017 Dec 27. pii: S1558-7673(17)30390-7. doi: 10.1016/j.clgc.2017.12.004. [Epub ahead of print]


Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels.

Campbell J, Ryan CJ, Lord CJ.

Methods Mol Biol. 2018;1711:83-99. doi: 10.1007/978-1-4939-7493-1_5.


HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.

Almassi N, Reichard C, Li J, Russell C, Perry J, Ryan CJ, Friedlander T, Sharifi N.

JAMA Oncol. 2018 Apr 1;4(4):554-557. doi: 10.1001/jamaoncol.2017.3159.


Can we usefully stratify patients according to suicide risk?

Large MM, Ryan CJ, Carter G, Kapur N.

BMJ. 2017 Oct 17;359:j4627. doi: 10.1136/bmj.j4627. No abstract available.


A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events.

Ryan CJ, Kennedy S, Bajrami I, Matallanas D, Lord CJ.

Cell Syst. 2017 Oct 25;5(4):399-409.e5. doi: 10.1016/j.cels.2017.09.011. Epub 2017 Oct 11.


Suicide risk assessment among psychiatric inpatients: a systematic review and meta-analysis of high-risk categories.

Large M, Myles N, Myles H, Corderoy A, Weiser M, Davidson M, Ryan CJ.

Psychol Med. 2018 May;48(7):1119-1127. doi: 10.1017/S0033291717002537. Epub 2017 Sep 6.


Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone.

Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Chi KN.

Clin Genitourin Cancer. 2017 Jul 25. pii: S1558-7673(17)30211-2. doi: 10.1016/j.clgc.2017.07.014. [Epub ahead of print]


Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.


Treatment strategies in low-volume metastatic castration-resistant prostate cancer.

Wei XX, Ko EC, Ryan CJ.

Curr Opin Urol. 2017 Nov;27(6):596-603. doi: 10.1097/MOU.0000000000000436. Review.


Authors' reply.

Ryan CJ, Newton-Howes G.

Br J Psychiatry. 2017 Aug;211(2):119-120. doi: 10.1192/bjp.211.2.119. No abstract available.


An alternative aide-mémoire to assist in the clinical assessment of suicidal patients: comment on Alyami et al.

Large M, Myles H, Ryan CJ.

Australas Psychiatry. 2017 Aug;25(4):414-415. doi: 10.1177/1039856217695708. No abstract available.


Genetic Interaction Score (S-Score) Calculation, Clustering, and Visualization of Genetic Interaction Profiles for Yeast.

Roguev A, Ryan CJ, Xu J, Colson I, Hartsuiker E, Krogan N.

Cold Spring Harb Protoc. 2018 Feb 1;2018(2):pdb.prot091983. doi: 10.1101/pdb.prot091983.


High-Throughput Quantitative Genetic Interaction Mapping in the Fission Yeast Schizosaccharomyces pombe.

Roguev A, Ryan CJ, Hartsuiker E, Krogan NJ.

Cold Spring Harb Protoc. 2018 Feb 1;2018(2):pdb.top079905. doi: 10.1101/pdb.top079905.


A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.

Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY.

Eur Urol. 2018 Feb;73(2):156-165. doi: 10.1016/j.eururo.2017.06.027. Epub 2017 Jul 14. Review.


CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer.

Bridgett S, Campbell J, Lord CJ, Ryan CJ.

Cell Syst. 2017 Jul 26;5(1):82-86.e3. doi: 10.1016/j.cels.2017.06.002. Epub 2017 Jul 12.


High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ.

Clin Genitourin Cancer. 2017 Dec;15(6):733-741.e1. doi: 10.1016/j.clgc.2017.05.026. Epub 2017 Jun 3.


Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES.

Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283.


Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer.

Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ.

Mol Cancer Res. 2017 Sep;15(9):1221-1229. doi: 10.1158/1541-7786.MCR-17-0196. Epub 2017 Jun 7.


Known unknowns and unknown unknowns in suicide risk assessment: evidence from meta-analyses of aleatory and epistemic uncertainty.

Large M, Galletly C, Myles N, Ryan CJ, Myles H.

BJPsych Bull. 2017 Jun;41(3):160-163. doi: 10.1192/pb.bp.116.054940. Review.


Suicide Rates After Discharge From Psychiatric Facilities: A Systematic Review and Meta-analysis.

Chung DT, Ryan CJ, Hadzi-Pavlovic D, Singh SP, Stanton C, Large MM.

JAMA Psychiatry. 2017 Jul 1;74(7):694-702. doi: 10.1001/jamapsychiatry.2017.1044. Review.


Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ.

Ther Adv Med Oncol. 2017 May;9(5):319-333. doi: 10.1177/1758834017698644. Epub 2017 Mar 22. Review.


Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.

Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR.

J Nucl Med. 2017 Dec;58(12):1956-1961. doi: 10.2967/jnumed.117.192476. Epub 2017 May 18.


In-patient suicide: selection of people at risk, failure of protection and the possibility of causation.

Large MM, Chung DT, Davidson M, Weiser M, Ryan CJ.

BJPsych Open. 2017 May 1;3(3):102-105. doi: 10.1192/bjpo.bp.116.004309. eCollection 2017 May.


Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY.

JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.


A substantial peer-worker workforce in a psychiatric service will improve patient outcomes - the case against.

O'Connor N, Clark S, Ryan CJ.

Australas Psychiatry. 2017 Oct;25(5):445-447. doi: 10.1177/1039856217700777. Epub 2017 May 4.


The use of community treatment orders in competent patients is not justified.

Newton-Howes G, Ryan CJ.

Br J Psychiatry. 2017 May;210(5):311-312. doi: 10.1192/bjp.bp.116.193920.


The histone variant H2A.Z promotes splicing of weak introns.

Nissen KE, Homer CM, Ryan CJ, Shales M, Krogan NJ, Patrick KL, Guthrie C.

Genes Dev. 2017 Apr 1;31(7):688-701. doi: 10.1101/gad.295287.116.


Suicide risk article points in the wrong direction.

Large M, Ryan CJ.

BMJ. 2017 Apr 21;357:j1965. doi: 10.1136/bmj.j1965. No abstract available.


The practicalities and ethics of ketamine for depression.

Ryan CJ, Loo C.

Lancet Psychiatry. 2017 May;4(5):354-355. doi: 10.1016/S2215-0366(17)30155-4. Epub 2017 Apr 5. No abstract available.


Interactions between police and people with mental illness.

Chappell D, Ryan CJ.

Aust N Z J Psychiatry. 2017 Apr;51(4):409-410. doi: 10.1177/0004867416682833. Epub 2016 Dec 14. No abstract available.


A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.

Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ.

Oncologist. 2017 May;22(5):503-e43. doi: 10.1634/theoncologist.2016-0432. Epub 2017 Mar 17.


Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ.

Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.


The correlates of physical activity among adult Métis.

Ryan CJ, Cooke M, Kirkpatrick SI, Leatherdale ST, Wilk P.

Ethn Health. 2017 Feb 28:1-20. doi: 10.1080/13557858.2017.1294655. [Epub ahead of print]


Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.

Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN.

J Clin Oncol. 2017 Apr 10;35(11):1231-1239. doi: 10.1200/JCO.2016.70.5350. Epub 2017 Feb 21.


Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI.

Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. doi: 10.1158/1078-0432.CCR-16-2509. Epub 2017 Feb 17.


A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.

Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ.

Urol Oncol. 2017 Apr;35(4):149.e7-149.e13. doi: 10.1016/j.urolonc.2016.11.005. Epub 2017 Feb 1.


Prostate Cancer Academy 2016: Presentation summaries.

Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ.

Rev Urol. 2016;18(4):205-213. doi: 10.3909/riuPCA2016. No abstract available.


Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

Massard C, Mateo J, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J.

Ann Oncol. 2017 Jan 1;28(1):90-95. doi: 10.1093/annonc/mdw441.


ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.

Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ.

Nat Commun. 2016 Dec 13;7:13837. doi: 10.1038/ncomms13837.


Commentary: Adverse experiences in psychiatric hospitals might be the cause of some postdischarge suicides.

Chung DT, Ryan CJ, Large MM.

Bull Menninger Clin. 2016 Fall;80(4):371-375.


Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.

Lancet Oncol. 2017 Jan;18(1):132-142. doi: 10.1016/S1470-2045(16)30560-5. Epub 2016 Nov 16.


Interdisciplinary Pain Education: Moving From Discipline-Specific to Collaborative Practice.

Patel B, Hacker E, Murks CM, Ryan CJ.

Clin J Oncol Nurs. 2016 Dec 1;20(6):636-643.


Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L.

Cancer Immunol Res. 2016 Nov;4(11):948-958. Epub 2016 Sep 29.

Supplemental Content

Support Center